Oxipit

The most AI central product in this index by a clear margin, because the AI does not assist a clinician, it replaces one for a defined slice of work. ChestLink identifies chest X-rays with no abnormality and produces finalized patient reports with no radiologist intervention at all. The broader CXR Suite detects 75 findings, which the company states covers roughly 90 percent of abnormalities radiologists encounter daily, plus a quality module that continuously re checks AI negative studies.

This vendor defines the far end of the autonomy axis and should be read carefully rather than simply admired. For high confidence normal studies there is no human in the loop by design: the report is finalized and issued autonomously. The safeguards are threshold based rather than review based, with the company reporting a 99 percent sensitivity metric translating to zero clinically relevant errors during piloting, more than 500,000 real world images processed in supervised operation for over a year before certification, an audit log for operational oversight, and a separate quality module re examining AI negative cases. The grade is B rather than A because the entire safety case rests on the confidence threshold holding in each deployment's case mix, which is a materially different risk posture than clinician review and demands local validation.

The regulatory bar itself forced disclosure most vendors never face, and the company published the operational specifics. Pre certification evaluation ran in supervised reporting across multiple pilot sites for more than a year on over 500,000 real world chest X ray images, with a stated 99 percent sensitivity threshold. The system is described as accounting for patient age, clinical context, and variation in radiologist subjectivity, and it produces an audit trail. Scope is quantified concretely at 75 detectable findings. For an autonomous product this level of published operating detail is the minimum acceptable, and unusually the company meets it.

Operational evidence is substantial and independent selection decisions add weight. The company reports autonomous handling of 15 to 40 percent of daily reporting workflow depending on institution type, validated across 500,000 plus images pre certification. Two European diagnostic groups selected the suite following structured multi vendor evaluations, one assessing three leading vendors across more than 700 real world cases. Deployment extends into low resource settings. What is missing is peer reviewed outcome evidence quantifying missed pathology rates in live autonomous operation, which is the study the category most needs and which the vendor best positioned to run has not published.

No published PHI or data governance framework was located. The audit log the company describes is a clinical safety mechanism rather than a data stewardship disclosure, and the two should not be conflated.

No HIPAA or BAA commitment located, consistent with a European vendor whose autonomous product is not available for autonomous use in the United States. GDPR rather than HIPAA is the operative regime for current deployments.

No SOC 2, ISO 27001, or equivalent attestation was located in the materials reviewed.

A genuinely unusual regulatory position that buyers must read precisely. ChestLink holds CE Class IIb certification, the first regulatory approval anywhere permitting an AI medical imaging application to perform diagnostic reporting autonomously, opening deployment across 32 European countries. Class IIb reflects the elevated validation standard required to let software complete a diagnostic task independently. Critically, the company states plainly that autonomous operation is CE marked and available in Europe and is not available for autonomous use in the United States. A US buyer therefore cannot deploy the capability that defines this vendor. Recent CE certified extensions cover chest CT and musculoskeletal X-ray.

No formal governance program was located, but two disclosed design elements do governance work: the system explicitly accounts for patient age and clinical context in its confidence determination, and a separate quality module continuously re checks AI negative studies, which is a standing false negative control rather than a one time validation. What is absent, and matters more here than for any assistive product in the index, is published subgroup analysis showing the confidence threshold holds across demographics, equipment, and disease prevalence, since an autonomous system's errors are never seen by a clinician.

Integrates directly into PACS workflow, with the company emphasizing minimal IT requirements and stated scalability from 5,000 to more than 500,000 radiographs per year. Deployments have run through third party AI orchestration platforms, and following the acquisition the product is available through the acquirer's AI marketplace, which gives customers of that imaging IT vendor a procurement path without separate integration. A web dashboard provides triage oversight and performance metrics.

No hosting, tenancy, or residency terms were located, though the emphasis on minimal IT requirements and PACS integration suggests flexibility about where inference runs.

No published pricing. The most consequential commercial fact is ownership rather than price: the company was acquired by a major imaging IT and cybersecurity vendor in a transaction completed April 2026, so procurement, roadmap, and support now run through that organization, and the product is distributed via its AI marketplace. Buyers should evaluate this as part of a larger vendor relationship rather than as an independent purchase.

Chest X-ray is the core and the only modality where the autonomous capability exists, with CE certified extensions into chest CT and musculoskeletal X-ray announced for 2026. Settings span hospital and outpatient diagnostic imaging in Europe, with the company citing deployments in resource limited health systems where radiologist scarcity is most acute, which is arguably where autonomous reporting has its strongest justification. United States buyers should treat this as a detection and triage product only.